SANTA CLARA — At SC24, NVIDIA announced the launch of its open-source BioNeMo Framework, a cutting-edge platform enabling global leaders in pharmaceuticals, biotechnology, and AI research to advance biomolecular science and accelerate drug discovery. Designed to address the challenges of scaling AI models in biomolecular research, BioNeMo brings supercomputing capabilities to biopharma, empowering researchers with tools to create life-saving treatments.

Advancing Biomolecular Science at Scale

The BioNeMo Framework offers specialized tools and datasets to accelerate the design of therapeutics, helping researchers analyze biological systems at unprecedented scales. Kimberly Powell, NVIDIA’s vice president of healthcare, highlighted its transformative potential: “The convergence of AI, accelerated computing, and expanding datasets opens unparalleled opportunities for the pharmaceutical industry. BioNeMo equips researchers worldwide with the capabilities to unravel biological complexities and fast-track the development of innovative treatments.”

Prominent organizations such as Argonne National Laboratory, Dyno Therapeutics, Genentech, Weights & Biases, and Ginkgo Bioworks are leveraging the platform to scale foundational biological models and accelerate discovery processes. Arvind Ramanathan, computational science group leader at Argonne, emphasized the platform’s accessibility: “BioNeMo offers an enterprise-level solution, enabling researchers without specialized computational expertise to train large biological models effectively.”

Introducing the Comprehensive BioNeMo Platform

The NVIDIA BioNeMo platform integrates seamlessly with accelerated computing infrastructure, offering a suite of tools to optimize AI model creation, customization, and deployment for molecular design and drug discovery. Key features include:

• BioNeMo Framework: A foundation for building large-scale AI biomolecular models.
• NVIDIA NIM™ Microservices: Scalable, secure AI inference tools deployable across diverse environments.
• BioNeMo Blueprints: Customizable reference workflows for wet-lab and computational tasks, designed to streamline molecular design processes.

Breakthrough Capabilities with NIM Microservices

Newly available NIM microservices support industry-leading models, delivering significant efficiency improvements:

• AlphaFold2: Predicts protein structures 5x faster for real-time insights.
• DiffDock 2.0: Accelerates molecular orientation predictions by 6.2x with 16% higher accuracy.
• RFdiffusion and ProteinMPNN: Expedite the design of novel proteins for therapeutic use.

The platform also introduces cuEquivariance, an advanced library that enhances chemical computation performance, further enabling breakthroughs in molecular modeling.

Blueprints for Scalable AI Deployments

BioNeMo Blueprints, a library of customizable workflows, empowers developers to scale AI applications into production pipelines. For example, the Blueprint for Virtual Screening offers a streamlined approach to designing small molecules, significantly reducing costs and time.

Global Adoption and Industry Integration

Over 200 organizations, including leading pharmaceutical companies and startups, are integrating BioNeMo into their workflows. Partners such as Accenture, AWS, and Deloitte are deploying BioNeMo Blueprints to help enterprises accelerate drug discovery globally.

Shaping the Future of Digital Biology

By combining open-source innovation with enterprise-grade solutions, NVIDIA BioNeMo is set to revolutionize biomolecular research and reshape the future of digital biology. The platform empowers scientists and companies to harness AI’s potential in advancing drug development and molecular design, driving impactful discoveries worldwide.

For more information, visit NVIDIA BioNeMo.